• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Neurology

Quick Take: Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

byDonna LeetandAliya Ramjaun
December 26, 2018
in Neurology, Oncology
Reading Time: 2 mins read
Glioblastoma phenotypes identified on MRI predict molecular behavior
Share on FacebookShare on TwitterShare on LinkedIn

Neoantigens are derived from tumor-specific somatic mutations. As such, they are exempt from immune central tolerance mechanisms and can generate robust immune responses, making them an ideal target for personalized cancer vaccines. Personalized neoantigen vaccination has been previously tested in patients with high-risk melanoma, a cancer that usually harbors a high mutation load. However, the concept has not yet been tested in tumors with a relatively low mutational load, such as glioblastoma (GBM). In this phase I/Ib study, 8 patients with newly diagnosed glioblastoma were immunized with personalized neoantigen vaccines following surgical resection and conventional radiotherapy to assess safety and feasibility. Immune responses were also studied. Vaccines contained up to 20 immunizing neoantigen peptides selected based on whole exome and RNA sequencing of surgically resected GBM and human leukocyte antigen (HLA) class I binding predictions, as well as polyinosinic and polycytidylic acid (poly-ICLC). The median time from surgery to vaccination was 19.9 weeks (range 17.1 to 24.7 weeks), and 6 of 8 patients required dexamethasone therapy during vaccine priming. Five patients did not complete booster vaccinations due to disease progression. Researchers found that patients who did not receive dexamethasone during vaccine priming generated robust de novo tumor-specific immune responses against multiple predicted neoantigens, demonstrated using ex vivo enzyme-linked immunospot (ELISPOT) and ex vivo intracellular cytokine staining assays. Moreover, T-cell receptor (TCR) sequencing and multiplex immunofluorescence revealed that there was an increase in tumor T cell infiltration and tumor-specific TCR clonotypes in these patients. However, patients who required dexamethasone did not generate statistically significant immune responses. Ultimately, all patients died of progressive disease, indicating that vaccine-induced T cell responses did not produce a sufficient anti-tumor response to prevent disease progression. No dose limiting toxicities were observed. Overall, this study suggests that neoantigen vaccination is a feasible therapeutic strategy in tumors with a low mutational burden, and given the success in patients not treated with dexamethasone, future studies will evaluate neoantigen vaccination combined with immune checkpoint blockade for GBM.

Click to read the study in Nature

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Mustang Bio & City of Hope: CAR-T Cell Therapy Extends Treatment Refractory Glioblastoma Survival

Disulfiram is not effective as an adjunctive therapy to standard chemotherapy for glioblastoma

Tags: glioblastomaNeoantigen
Previous Post

Mupirocin effective in Staphylococcus aureus decolonization in neonates

Next Post

Quick Take: Small for gestational age and risk of childhood mortality: A Swedish population study

RelatedReports

Cardiovascular risk factors related to brain volume and associated dementia
2 Minute Medicine

Mustang Bio & City of Hope: CAR-T Cell Therapy Extends Treatment Refractory Glioblastoma Survival

April 7, 2024
Glioblastoma phenotypes identified on MRI predict molecular behavior
Chronic Disease

Disulfiram is not effective as an adjunctive therapy to standard chemotherapy for glioblastoma

April 6, 2023
Glioblastoma phenotypes identified on MRI predict molecular behavior
Neurology

Adding autologous tumor lysate-loaded dendritic cell vaccination to standard of care associated with clinical improvement in overall survival for patients with newly diagnosed and recurrent glioblastoma

November 26, 2022
#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction
StudyGraphics

#VisualAbstract: Carboplatin holds potential as an adjunct therapy for recurrent high-grade glioma treatment

January 14, 2021
Next Post

Quick Take: Small for gestational age and risk of childhood mortality: A Swedish population study

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

New molecular probes for melanoma imaging and treatment [PreClinical]

LUNG-RADS criteria increases positive predictive value for lung cancer detection in high-risk patients [Classics Series]

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.